417 results on '"Hopkins, Ashley M."'
Search Results
2. Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials
3. A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies
4. Exploring the role of sporadic BRAF and KRAS mutations during colorectal cancer pathogenesis: A spotlight on the contribution of the endosome-lysosome system
5. Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation
6. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies
7. Altered endosomal-lysosomal biogenesis in melanoma
8. Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer
9. A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma
10. Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy
11. Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials.
12. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150
13. Proteomic profiling of paired human liver homogenate and tissue derived extracellular vesicles.
14. A literature review of treatment-specific clinical prediction models in patients with breast cancer
15. Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine
16. Health Disinformation Use Case Highlighting the Urgent Need for Artificial Intelligence Vigilance
17. The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data
18. The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib
19. Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients
20. Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma
21. Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab
22. Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients
23. Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin
24. Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine
25. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials
26. Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages
27. Insights into Melanoma Clinical Practice: A Perspective for Future Research
28. Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis
29. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis
30. Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure
31. Prediction of Prostate Cancer Biochemical and Clinical Recurrence Is Improved by IHC-Assisted Grading Using Appl1, Sortilin and Syndecan-1
32. Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
33. Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials
34. Health Disinformation Use Case Highlighting the Urgent Need for Artificial Intelligence Vigilance: Weapons of Mass Disinformation.
35. Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma
36. Supplementary Data: R analysis code from Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab
37. Supplementary Data from Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab
38. Supplementary Results from Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab
39. Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials
40. Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift
41. Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials
42. Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer
43. Putting recommendations into practice: Australian rheumatologists’ opinions on leflunomide use in rheumatoid arthritis
44. Response to Mazzaschi and Buti
45. Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
46. C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab
47. Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease‐modifying antirheumatic drugs have influenced the use of leflunomide
48. Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability
49. Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs
50. Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.